About NewLimit
NewLimit is a company based in San Francisco (United States) founded in 2022 by Jacob Kimmel, Brian Armstrong, and Blake Byers.. NewLimit has raised $247.25 million across 3 funding rounds from investors including Kleiner Perkins, Khosla Ventures and Dimension Venture Partners. The company has 9 employees as of October 31, 2024. NewLimit offers products and services including Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program. NewLimit operates in a competitive market with competitors including Evotec, Crown Bioscience, Alloy Therapeutics, CatSci and NIH, among others.
- Headquarter San Francisco, United States
- Employees 9 as on 31 Oct, 2024
- Founders Jacob Kimmel, Brian Armstrong, Blake Byers
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$247.25 M (USD)
in 3 rounds
-
Latest Funding Round
$45 M (USD), Series B
Oct 20, 2025
-
Investors
Kleiner Perkins
& 14 more
-
Employee Count
9
as on Oct 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NewLimit
NewLimit offers a comprehensive portfolio of products and services, including Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medicines that restore youthful function in aging cells via reprogramming.
Program targeting aging immune systems for functional restoration.
Interventions to rejuvenate liver cells in aging processes.
Unlock access to complete
Unlock access to complete
Funding Insights of NewLimit
NewLimit has successfully raised a total of $247.25M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $45 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $45.0M
-
First Round
First Round
(08 May 2023)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - NewLimit | Valuation | Lilly |
|
| May, 2025 | Amount | Series B - NewLimit | Valuation | Kleiner Perkins | |
| May, 2023 | Amount | Series A - NewLimit | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NewLimit
NewLimit has secured backing from 15 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kleiner Perkins, Khosla Ventures and Dimension Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and defense sectors.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in early-stage tech startups
|
Founded Year | Domain | Location | |
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NewLimit
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NewLimit
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Newlimit Comparisons
Competitors of NewLimit
NewLimit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Alloy Therapeutics, CatSci and NIH, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug discovery and development services are provided to biopharma sector.
|
|
| domain | founded_year | HQ Location |
Cancer and CVMD drugs are developed using PDX models.
|
|
| domain | founded_year | HQ Location |
Drug discovery services are provided for therapeutic development.
|
|
| domain | founded_year | HQ Location |
Drug discovery services are provided to pharmaceutical clients worldwide.
|
|
| domain | founded_year | HQ Location |
Drug discovery services are provided to the biopharma sector.
|
|
| domain | founded_year | HQ Location |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Newlimit
Frequently Asked Questions about NewLimit
When was NewLimit founded?
NewLimit was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Where is NewLimit located?
NewLimit is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is NewLimit a funded company?
NewLimit is a funded company, having raised a total of $247.25M across 3 funding rounds to date. The company's 1st funding round was a Series A of $72.25M, raised on May 08, 2023.
How many employees does NewLimit have?
As of Oct 31, 2024, the latest employee count at NewLimit is 9.
What does NewLimit do?
Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension. It focuses on restoring youthful function in old cells by reprogramming the epigenome. The company leverages technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify epigenetic features of aging and discover interventions for rejuvenation. Its initial programs target the aging liver, immune, and vascular systems, with the long-term goal of significantly extending human healthspan through medicines for diseases associated with aging.
Who are the top competitors of NewLimit?
NewLimit's top competitors include Evotec, Crown Bioscience and NIH.
What products or services does NewLimit offer?
NewLimit offers Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program.
Who are NewLimit's investors?
NewLimit has 15 investors. Key investors include Kleiner Perkins, Khosla Ventures, Dimension Venture Partners, Founders Fund, and Eric Schmidt.